会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • METHODS FOR THE ISOLATION OF EXTRACELLULAR VESICLES AND OTHER BIOPARTICLES FROM URINE AND OTHER BIOFLUIDS
    • 从尿液和其他生物流体中分离细胞外细菌和其他生物物质的方法
    • WO2016022654A1
    • 2016-02-11
    • PCT/US2015/043768
    • 2015-08-05
    • YMIR GENOMICS LLC
    • PENDERGRAST, P. ShannonPENDERGRAST, R. ScottPENDERGRAST, J. StephenMARKOWSKA, Anna Irmina
    • C12N5/07B01D9/02B01D21/26C07K1/30C07K14/705
    • B01D9/0054B01D21/26B01D21/262B01D2009/0086C07K1/30C07K1/303C07K1/306C07K14/705C12N15/1003G01N1/4055
    • Compositions and methods for the isolation of protein-nucleic acid complexes and microvesicles (collectively referred to as "bioparticles") released by mammalian cells into body fluids or cell culture media are provided. Isolated bioparticles of the invention contain biological molecules that are useful as diagnostic/prognostic biomarkers or for identification of therapeutic targets (e.g., disease or disorder-associated miRNAs). The isolation of biological molecules as described herein results in purification and concentration of the molecules. Methods for producing bio fluids that are free of detectable bioparticles, that are largely depleted of bioparticles, or that possess a reduced concentration of bioparticles compared to a bio fluid starting material (collectively termed "bioparticle-depleted") are also provided. Isolation of bioparticle-depleted biofluid is useful, e.g„ in experimental systems where it is desirable to use a biofluid that does not contain endogenous bioparticles, or has been substantially depleted of endogenous bioparticles, from the source material.
    • 提供了将哺乳动物细胞释放到体液或细胞培养基中的蛋白质 - 核酸复合物和微泡(统称为“生物颗粒”)的分离的组合物和方法。 本发明的分离的生物颗粒含有可用作诊断/预后生物标志物或用于鉴定治疗靶点(例如疾病或病症相关miRNA)的生物分子。 如本文所述分离生物分子导致分子的纯化和浓缩。 还提供了生产生物流体的生物流体的方法,其与生物流体起始材料(统称为“生物颗粒耗尽”)相比,大部分耗尽生物颗粒,或具有降低的生物颗粒浓度的生物颗粒。 生物颗粒耗尽的生物流体的分离是有用的,例如“在需要从源材料中使用不含内源性生物颗粒或已经基本上耗尽内源性生物颗粒的生物流体的实验系统中。
    • 2. 发明申请
    • ANTIINFECTIVE PLANT NUCLEOPROTEIN ISOLATES
    • 抗生素植物核糖核酸分离株
    • WO2012030268A1
    • 2012-03-08
    • PCT/SE2011/000144
    • 2011-08-01
    • ROTHMAN, Ulf
    • ROTHMAN, Ulf
    • C07K1/14C07K14/415
    • C07K1/36A61K36/899C07K1/303C07K14/415
    • Foam fractionation is disclosed as a method for nucleoprotein capture and concentration from plant extracts without DNA or starch contamination. Plant nuclear proteins are first extracted by dilute acid or high-salt. Air is introduced as bubbles in the plant extract until foam formation. The foam is recovered and broken into a concentrated plant nuclear protein mixture which contains natural anti-infective histones, which are both antimicrobial and antiviral. The invention relates to a process for isolation of nucleoproteins from the plant kingdom, to the use thereof, or to a biocide and pharmaceutical product comprising an anti-infective nucleoprotein isolate. Plant histones prepared by foam capture represents an essentially unlimited source for natural, biodegradable peptide antibiotics and antivirals.
    • 公开了泡沫分馏作为从没有DNA或淀粉污染的植物提取物中进行核蛋白捕获和浓缩的方法。 植物核蛋白首先用稀酸或高盐提取。 空气在植物提取物中作为气泡引入直到泡沫形成。 将泡沫回收并破碎成浓缩的植物核蛋白混合物,其含有抗微生物和抗病毒的天然抗感染组蛋白。 本发明涉及从植物界分离核蛋白的方法,其用途,或涉及包含抗感染性核蛋白分离物的杀生物剂和药物产品。 通过泡沫捕获制备的植物组蛋白基本上是天然的,可生物降解的肽抗生素和抗病毒药物的无限来源。
    • 4. 发明申请
    • FRACTIONATION METHOD
    • 分馏方法
    • WO2015126330A3
    • 2015-11-05
    • PCT/SG2015050023
    • 2015-02-17
    • AGENCY SCIENCE TECH & RES
    • GAGNON PETER STANLEY
    • C07K1/34
    • C07K1/36C07K1/18C07K1/22C07K1/303C07K1/34C07K16/00C07K16/065C07K16/32
    • A method of purifying an IgG antibody from a preparation which includes providing the preparation in a form having substantially reduced chromatin levels from that of the sample from which the preparation was obtained and contacting the preparation with an electropositive membrane having a porosity that retains at least 50% of non-adsorbed solutes with a hydrodynamic diameter greater than a selected size but permits passage of non-adsorbed solutes with a hydrodynamic diameter less than the selected size, wherein the selected size is between about 10 nm and about 15 nm, where during at least a portion of the contacting step the preparation includes a salt such that (1) when present at a concentration less than 50 mM, a pH value is in a range from about 3 to within 0.5 pH units of the isoelectric point of the most alkaline glycoform of the IgG antibody in the preparation; or (2) when present at concentration greater than 50 mM, a pH value of the preparation is in a range from 3 to 9,, and adjusting operating conditions to the highest pH and lowest salt concentration that does not result in more than 5% of the antibody being bound to the membrane.
    • 一种从制剂中纯化IgG抗体的方法,该方法包括提供制剂的染色质水平与获得制剂的样品的染色质水平相比显着降低,并使制剂与孔隙率保持至少为50的正电膜接触 %流体动力学直径大于选定大小的未吸附溶质,但允许流体动力学直径小于所选大小的非吸附溶质通过,其中所选大小在大约10nm和大约15nm之间,其中在at (1)当以低于50mM的浓度存在时,pH值在约3至0.5碱性单位的最碱性等电点范围内 制剂中IgG抗体的糖型; 或(2)当以高于50mM的浓度存在时,制剂的pH值在3至9的范围内,并且调节操作条件至最高pH和最低盐浓度,其不会导致超过5% 的抗体结合到膜上。
    • 5. 发明申请
    • METHODS TO PRODUCE A PURIFIED PEPTIDE CHAIN FRACTION
    • 生产纯化肽链分段的方法
    • WO2012078936A3
    • 2014-04-17
    • PCT/US2011064052
    • 2011-12-09
    • GLAXOSMITHKLINE LLCDIENER ANDREA SGREENE DAVID C
    • DIENER ANDREA SGREENE DAVID C
    • A61K38/20
    • C07K1/303
    • Methods to produce a purified peptide chain fraction are disclosed. The methods comprise the step of adding a hexadecyltrimethylammonium salt to a first liquid portion containing a peptide chain of interest and the step of adjusting the pH of the second liquid portion. One aspect of the disclosure is a method of producing a purified peptide chain fraction comprising the steps of: a) providing a first liquid portion containing a peptide chain of interest; b) adding a exadecyltrimethylammonium salt to the first liquid portion to obtain a second liquid portion containing about 9.6 mM to about 13.72 mM of the hexadecyltrimethylammonium salt; c) adjusting the pH of the second liquid portion to a pH of about 4.3 to about 7.5; and d) separating the second liquid portion into an insoluble fraction and a purified peptide chain fraction containing the peptide chain of interest; whereby a purified peptide chain fraction is produced.
    • 公开了产生纯化肽链部分的方法。 所述方法包括将十六烷基三甲基铵盐加入到含有目标肽链的第一液体部分和调节第二液体部分的pH的步骤。 本公开的一个方面是制备纯化的肽链级分的方法,包括以下步骤:a)提供含有目的肽链的第一液体部分; b)向第一液体部分加入十九烷基三甲基铵盐,得到含有约9.6mM至约13.72mM十六烷基三甲基铵盐的第二液体部分; c)将第二液体部分的pH调节至约4.3至约7.5的pH; 和d)将第二液体部分分离成不溶性级分和含有目的肽链的纯化肽链级分; 从而产生纯化的肽链级分。